SecBot SecBot
SECBOTREPLAY Home › Report › ARGX

ARGX · Phase 3 ALKIVIA positive

ARGENX SE · 6-K filed Nov 9, 2026 at 08:01 ET

At the news

BULLISHIMPACT 6/10

6-K filed Nov 9, 2026 at 08:01 ET

argenx announced positive Phase 3 ALKIVIA data for efgartigimod in autoimmune myositis, meeting the primary endpoint in the combined IMNM and DM population with a statistically significant 15.4-point greater improvement in Total Improvement Score at Week 52 versus placebo. The company plans to submit an sBLA to the FDA for efgartigimod in IMNM by end of 2026, supported by Breakthrough Therapy Designation. This is a clinical data press release, not a periodic financial results release.

  • Phase 3 ALKIVIA met primary endpoint in combined IMNM and DM population: 15.4-point greater improvement in mean TIS at Week 52 vs placebo (p=0.0011; 48.0 vs 32.6).
  • IMNM patients showed 14.8-point greater improvement in mean TIS vs placebo (p=0.0048; 45.1 vs 30.2).
  • DM patients showed 14.5-point greater improvement in mean TIS vs placebo (p=0.1093; 51.5 vs 37.0), not statistically significant.
  • argenx plans to submit sBLA to FDA for efgartigimod in IMNM by end of 2026, supported by Breakthrough Therapy Designation.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access